A protective immune response in mice to viral components other than hemagglutinin in A live influenza a virus vaccine model

Vaccine

Volumn 22, Issue 17-18, 2004, Pages 2244-2247

  Horimoto, Taisuke ^a,b   Takada, Ayato ^a,b   Iwatsuki Horimoto, Kiyoko ^a,b   Kawaoka, Yoshihiro ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antigenic drift; Influenza virus; Live vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; FACIAL BONE; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA VIRUS A; LETHAL DOSE; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL; VIRUS INFECTION; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; NASAL CAVITY; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED;

EID: 2442454642     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.019     Document Type: Article

References (22)

1. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. 4th ed. Philadelphia: Williams & Wilkins; 2001:1533-79.
2. Potter C.W. Attenuated influenza virus vaccines. Rev Med Virol. 4:1994;279-292
3. Murphy B.R., Coelingh K. Principles underlying the development and use of live, attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 15:2002;295-323
4. Wareing M.D., Tannock G.A. Live attenuated vaccines against influenza; an historical review. Vaccine. 19:2001;3320-3330
5. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 136:2000;168-175
6. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 282:1999;137-144
7. Horimoto T., Takada A., Iwatsuki-Horimoto K., Hatta M., Goto H., Kawaoka Y. Generation of influenza A virus with chimeric (type A/B) hemagglutinins. J Virol. 77:2003;8031-8088
8. Hatta M., Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro. J Virol. 77:2003;6050-6054
9. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA. 96:1999;9345-9350
10. Kida H., Brown L.E., Webster R.G. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology. 122:1982;38-47
11. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 82:1985;1785-1789
12. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749
13. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol. 152:1994;1653-1661
14. O'Neill E., Krauss S.L., Riberdy J.M., Webster R.G., Woodland D.L. Heterologous protection against lethal A/Hong Kong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol. 81:2000;2689-2696
15. Kilbourne E.D., Laver W.G., Schulman J.L., Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol. 2:1968;281-288
16. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. New Engl J Med. 286:1972;1329-1332
17. Chen Z., Kadowaki S., Hagiwara Y., Yoshikawa T., Matsuo K., Kurata T., et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine. 18:2000;3214-3222
18. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 21:2003;3212-3218
19. Horimoto T., Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev. 14:2001;129-149
20. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 279:1998;393-396
21. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477
22. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet. 354:1999;916-917